Starsource Multitrade Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Starsource Multitrade Ltd is ₹ 108.5 as of 12 Jun 15:30 . The P/E Ratio of Starsource Multitrade Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Starsource Multitrade Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Starsource Multitrade Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 15070 crore as compare to the Dec '25 revenue of ₹ 16099 crore. This represent the decline of -6.39% The ebitda of Starsource Multitrade Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 4412 crore as compare to the Dec '25 ebitda of ₹ 5037 crore. This represent the decline of -12.41% The net profit of Starsource Multitrade Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 2723 crore over 8 quarters. This represents a CAGR of -2.60% The Dividend Payout of Starsource Multitrade Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Starsource Multitrade Ltd

Starsource Multitrade Limited was initially established on August 17, 1942 under the name 'Chemo Pharma Laboratories Limited'.
Name of the Company is given a change in name with due approval from Registrar of Companies effected on August 12, 2025.
Initially, the Company had been making Pharmaceuticals and also diversified into bulk drugs. However due to increase in competition and flow of new drugs, the Company had to dispose the business and pay all its liabilities and dues.
Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential.
The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals. The existing Main Objects of Clause III (A) be altered by replacing the same with the following new Clause to carry on the business of buying, selling, reselling, importing, exporting, transporting, storing, promoting, marketing or supplying, trading, dealing in any manner whatsoever in all type of goods and commodities on retail as well as on wholesale basis in India or elsewhere during the year 2025.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Starsource Multitrade Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Starsource Multitrade Ltd is 16 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 433,619 Cr

What are the key factors driving the stock performance of Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd?

As of June 14, 2026, the Starsource Multitrade Ltd stock price is INR ₹108.5. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1807.25.

How do dividend payouts of Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Starsource Multitrade Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.